4 news items
TNF Pharmaceuticals Prepares To Advance MYMD-1, Targeting Age-Related Decline
TNFA
21 Aug 24
"), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions
TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol "TNFA" Effective Before Market Open Today
TNFA
24 Jul 24
stage biopharmaceutical company committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today
MyMD Pharmaceuticals Announces Corporate Rebranding To New Name TNF Pharmaceuticals, To Begin Under The New Trading Symbol "TNFA" Effective July 24, 2024
TNFA
22 Jul 24
committed to developing novel therapies for age-related diseases and autoimmune and inflammatory conditions, today announced a rebranding to the new name
MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
TNFA
17 Jun 24
. (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage biopharmaceutical company committed
- Prev
- 1
- Next